Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
description
Transcript of Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
![Page 1: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/1.jpg)
Asthma – 2005
“Why We Do the Things We Do”
A Miniature Literature Review
Michael E. Ruff, MD
Dallas, Texas
![Page 2: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/2.jpg)
![Page 3: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/3.jpg)
![Page 4: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/4.jpg)
![Page 5: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/5.jpg)
![Page 6: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/6.jpg)
![Page 7: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/7.jpg)
![Page 8: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/8.jpg)
![Page 9: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/9.jpg)
![Page 10: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/10.jpg)
![Page 11: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/11.jpg)
![Page 12: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/12.jpg)
![Page 13: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/13.jpg)
![Page 14: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/14.jpg)
![Page 15: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/15.jpg)
![Page 16: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/16.jpg)
Photo: Personal collection, Dr. Dennis Williams Pharm.D.
![Page 17: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/17.jpg)
![Page 18: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/18.jpg)
![Page 19: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/19.jpg)
![Page 20: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/20.jpg)
![Page 21: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/21.jpg)
![Page 22: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/22.jpg)
![Page 23: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/23.jpg)
![Page 24: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/24.jpg)
![Page 25: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/25.jpg)
![Page 26: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/26.jpg)
![Page 27: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/27.jpg)
![Page 28: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/28.jpg)
![Page 29: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/29.jpg)
![Page 30: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/30.jpg)
![Page 31: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/31.jpg)
![Page 32: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/32.jpg)
![Page 33: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/33.jpg)
![Page 34: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/34.jpg)
![Page 35: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/35.jpg)
![Page 36: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/36.jpg)
![Page 37: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/37.jpg)
![Page 38: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/38.jpg)
![Page 39: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/39.jpg)
![Page 40: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/40.jpg)
![Page 41: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/41.jpg)
![Page 42: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/42.jpg)
![Page 43: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/43.jpg)
![Page 44: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/44.jpg)
![Page 45: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/45.jpg)
Effect of Inhaled Corticosteroids on Inflammation
Pre– and post–3-month treatment with budesonide (BUD) 600 mcg b.i.d.
E = Epithelium
BM = Basement Membrane
Laitinen et al. J Allergy Clin Immunol. 1992;90:32-42. Reprinted with permission.
![Page 46: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/46.jpg)
![Page 47: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/47.jpg)
![Page 48: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/48.jpg)
![Page 49: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/49.jpg)
Mean Annual Increase in FEV1 During ICS Therapy
12
10
8
6
4
2
0
AnnualChange in
% PredictedFEV1
<2 2-3 3-5 >5
Asthma Duration at Start of ICS therapy (yrs)
Agertoft L, Pederson S. Respir Med. 1994; 88:373-381.
![Page 50: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/50.jpg)
![Page 51: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/51.jpg)
![Page 52: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/52.jpg)
![Page 53: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/53.jpg)
![Page 54: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/54.jpg)
![Page 55: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/55.jpg)
![Page 56: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/56.jpg)
![Page 57: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/57.jpg)
![Page 58: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/58.jpg)
![Page 59: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/59.jpg)
![Page 60: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/60.jpg)
Assessment of the Effects of Inhaled Corticosteroids on Growth
cm
0 1 2 3 4
Time (y)
0
130
135
140
150
160
145
155
Standing Height
*Children aged 5 to 12 years.Childhood Asthma Management Program Research Group. N Engl J Med. 2000;343:1054-63.
Standing-Height Velocity
cm
/y
Time (y)0 1 2 3 4
0.0
4.5
5.0
5.5
6.5
6.0
Nedocromil PlaceboBudesonide
![Page 61: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/61.jpg)
![Page 62: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/62.jpg)
![Page 63: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/63.jpg)
Girls
Boys
Mea
sure
d A
dult
Hei
ght
(cm
)
Target Adult Height (cm)
200
190
180
170
160
150150 160 170 180 190 200
Effect of Long-term Treatment with Inhaled Budesonide on Adult Height in Children with Asthma
Agertoft L, Pedersen S. N Engl J Med. 2000;343:1064-1069.
![Page 64: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/64.jpg)
![Page 65: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/65.jpg)
![Page 66: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/66.jpg)
![Page 67: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/67.jpg)
NIH Treatment Guidelines
NIH-preferred options are highlighted.
Guidelines for the Diagnosis and Management of Asthma. 2002.NIH Publication No. 02-5075.
• Step 1 - Mild Intermittent Asthma– No daily medication
• Step 2 - Mild Persistent Asthma– Low-dose inhaled corticosteroid (ICS)– Cromolyn/nedocromil, theophylline or leukotriene modifier
(alternative Rx)• Step 3 - Moderate Persistent Asthma
– Low to medium dose ICS + long-acting β2-agonist (LABA)– Medium-dose ICS – Low or medium ICS + LTRA or theophylline (alternative Rx)
• Step 4 - Severe Persistent Asthma– High-dose ICS + LABA– If needed, add oral steroids
![Page 68: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/68.jpg)
![Page 69: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/69.jpg)
![Page 70: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/70.jpg)
![Page 71: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/71.jpg)
![Page 72: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/72.jpg)
![Page 73: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/73.jpg)
NIH Treatment Guidelines
NIH-preferred options are highlighted.
Guidelines for the Diagnosis and Management of Asthma. 2002.NIH Publication No. 02-5075.
• Step 1 - Mild Intermittent Asthma– No daily medication
• Step 2 - Mild Persistent Asthma– Low-dose inhaled corticosteroid (ICS)– Cromolyn/nedocromil, theophylline or leukotriene modifier
(alternative Rx)• Step 3 - Moderate Persistent Asthma
– Low to medium dose ICS + long-acting β2-agonist (LABA)– Medium-dose ICS – Low or medium ICS + LTRA or theophylline (alternative Rx)
• Step 4 - Severe Persistent Asthma– High-dose ICS + LABA– If needed, add oral steroids
![Page 74: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review](https://reader035.fdocuments.in/reader035/viewer/2022062217/56814c56550346895db9719f/html5/thumbnails/74.jpg)
• Teach and re-teach and re-check inhaler technique• Always assume that patients are poorly compliant,
especially if their asthma is poorly controlled • Monitor objective parameters of airway function (i.e.,
spirometry)• Assume that most asthmatics (and almost all children with
asthma) are allergic• Identify and counsel avoidance for triggering factors• Treat allergic rhinitis• Consider allergen-specific immunotherapy (i.e.,
allergy shots)• Realize that the natural history of persistent asthma is not
benign• Identify persistent asthmatics as early as possible and
institute treatment with anti-inflammatory agents• Monitor for drug side effects (e.g., plot growth curves), and
attempt to use the lowest effective therapeutic dose of inhaled corticosteroids